ARROWHEAD PHARMACEUTICALS, INC. Deferred Revenue (Non-Current)
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) had Deferred Revenue (Non-Current) of $625.00 thousand as of 2017-06-30, per its 10-Q filed 2017-08-03.
Discontinued › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredRevenueNoncurrent · last filed 2017-12-12
- 2017-06-30: Deferred Revenue, Noncurrent $625.00K.
- 2017-03-31: Deferred Revenue, Noncurrent $1.25M.
- 2016-12-31: Deferred Revenue, Noncurrent $5.18M.
- 2016-09-30: Deferred Revenue, Noncurrent $2.50M.
| Period end | Deferred Revenue, Noncurrent |
|---|---|
| 2017-06-30 | $625.00K 10-Q · filed 2017-08-03 |
| 2017-03-31 | $1.25M 10-Q · filed 2017-05-03 |
| 2016-12-31 | $5.18M 10-Q · filed 2017-02-06 |
| 2016-09-30 | $2.50M 10-K · filed 2017-12-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |